A.O. RUBANENKO, YU.V. SCHUKIN

Samara State Medical University, 89 Chapaevskaya St., Samara, Russian Federation, 443099

Rubanenko A.O. — Cand. of Med. Sc., Assistant of the Department of Propaedeutic Therapy, tel. +7-927-201-09-44, e-mail: anatolii.rubanenko@gmail.com

Schukin Yu.V. — D. Med. Sc., Head of the Department of Propaedeutic Therapy, tel. +7-927-262-09-03, e-mail: samgmu_pt@mail.ru

This article is related to investigation of the associations between VKORC1 C1173T gene polymorphism and haemostatic indicators in patients with permanent atrial fibrillation. There were studied 182 patients with coronary heart disease and permanent atrial fibrillation; mean age was 64±9.8 years. The study showed that in patients with permanent atrial fibrillation the presence of VKORC1 CC genotype was accompanied by an increase of thrombin—activatable fibrinolysis inhibitor of more than 205% and also soluble fibrin monomer complexes of more than 10 mg%.

Key words: genetic polymorphisms, vitamin К epoxide reductase complex, subunit 1 (VKORC1), hemostasis, thrombin—activatable fibrinolysis inhibitor (TAFI), atrial fibrillation.

REFERENCES

1. Diagnostika i lechenie fibrillyatsii predserdiy. Rekomendatsii RKO, VNOA i ASSKh [Diagnosis and treatment of atrial fibrillation. Recommendations RKO, and VNOA ASSKH]. Moscow, 2012.
2. Danese E., Montagnana M., Cervelin G., Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med., 2014, vol. 27, pp. 1-8.
3. Hijazi Z., Oldgren J., Siegbahn A., Granger C.B. et al. Biomarkers in atrial fibrillation: a clinical review. Eur Heart J., 2013, vol. 34(20), pp. 1475-80.
4. Ząbczyk M., Lelakowski J. Thromboembolic events are associated with prolonged clot lysis time in patients with permanent atrial fibrillation. Pol Arch Med Wewn., 2011, vol. 121(11), pp. 400-407.
5. Nahar R., Saxena R., Deb R. et al. CYP2C9, VKORC1, CYP4F2, ABCB1 and F5 variants: Influence on quality of long-term anticoagulation. Pharmacol Rep., 2014, vol. 66(2), pp. 243-9
6. Pirmohamed M., Burnside G., Eriksson N. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med, 2013, vol. 369 (24), pp. 2294-303.